Header cover image

U.S. Biotech Industry Analysis

UpdatedJun 01, 2024
DataAggregated Company Financials
Companies574
  • 7D-0.3%
  • 3M-6.8%
  • 1Y5.4%
  • YTD-0.7%

In the last week, the Biotech industry is flat overall, with Moderna standing out by going down 14%. The past year has been better, since the industry has gained 5.4% in that time. As for the next few years, earnings are expected to grow by 25% per annum.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 01 Jun 2024US$1.1tUS$164.6b-US$26,677,227,566.3227.4x-41.6x6.7x
Mon, 29 Apr 2024US$1.1tUS$164.6b-US$27,372,800,636.0922.6x-39.1x6.5x
Wed, 27 Mar 2024US$1.2tUS$164.4b-US$23,792,606,116.0221.2x-48.8x7.1x
Fri, 23 Feb 2024US$1.2tUS$169.0b-US$20,212,652,991.5813.2x-57x6.8x
Sun, 21 Jan 2024US$1.4tUS$204.8b-US$22,506,538,466.0018.5x-63.3x7x
Tue, 19 Dec 2023US$1.4tUS$204.7b-US$22,117,247,361.0019.2x-61x6.6x
Thu, 16 Nov 2023US$1.2tUS$204.7b-US$22,143,559,902.0018.4x-55.1x6x
Sat, 14 Oct 2023US$1.3tUS$207.3b-US$13,141,713,262.0016.6x-96.4x6.1x
Mon, 11 Sep 2023US$1.3tUS$207.5b-US$12,633,744,533.0017.4x-101x6.1x
Wed, 09 Aug 2023US$1.3tUS$206.4b-US$12,500,248,802.0016.4x-101x6.1x
Fri, 07 Jul 2023US$1.1tUS$186.2b-US$16,056,868,924.0013.2x-69.5x6x
Sun, 04 Jun 2023US$1.1tUS$185.9b-US$16,014,255,509.0011.4x-71.1x6.1x
Tue, 02 May 2023US$1.2tUS$197.0b-US$6,677,740,450.0014x-175.7x6x
Thu, 30 Mar 2023US$1.1tUS$198.3b-US$4,280,712,821.0013.8x-266.8x5.8x
Sat, 25 Feb 2023US$1.1tUS$200.5b-US$3,797,679,065.0014.2x-295.4x5.6x
Mon, 23 Jan 2023US$1.2tUS$203.8bUS$1.8b14.4x655.9x5.7x
Wed, 21 Dec 2022US$1.2tUS$203.3bUS$1.6b14.6x704x5.7x
Fri, 18 Nov 2022US$1.1tUS$202.2bUS$1.2b14.7x921.2x5.5x
Sun, 16 Oct 2022US$1.0tUS$206.0bUS$5.4b15.6x194.3x5.1x
Tue, 13 Sep 2022US$1.1tUS$206.9bUS$5.9b15.8x185.7x5.3x
Thu, 11 Aug 2022US$1.1tUS$208.3bUS$5.7b16.6x196.3x5.4x
Sat, 09 Jul 2022US$1.1tUS$211.5bUS$10.8b17.4x102.3x5.2x
Mon, 06 Jun 2022US$1.0tUS$212.8bUS$11.3b16.4x88.7x4.7x
Wed, 04 May 2022US$1.0tUS$201.1bUS$7.4b17.2x140.3x5.2x
Fri, 01 Apr 2022US$1.3tUS$221.5bUS$11.4b19.1x111.5x5.7x
Sun, 27 Feb 2022US$1.2tUS$222.9bUS$10.9b19.5x113.2x5.5x
Tue, 25 Jan 2022US$1.2tUS$212.0bUS$2.5b23.8x496.5x5.8x
Thu, 23 Dec 2021US$1.4tUS$212.0bUS$2.8b27.2x511.5x6.8x
Sat, 20 Nov 2021US$1.4tUS$212.2bUS$3.3b27.3x442.8x6.8x
Mon, 18 Oct 2021US$1.5tUS$196.3b-US$2,601,699,037.0023.6x-565.4x7.5x
Wed, 15 Sep 2021US$1.6tUS$196.4b-US$2,312,118,480.5621.6x-682.1x8x
Fri, 13 Aug 2021US$1.6tUS$197.0b-US$1,662,914,785.5822.7x-936x7.9x
Tue, 08 Jun 2021US$1.4tUS$174.8b-US$11,505,542,875.5522.2x-120.4x7.9x
Price to Earnings Ratio

-120.4x


Total Market Cap: US$1.4tTotal Earnings: -US$11,505,542,875.55Total Revenue: US$174.8bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -22.9x202220232024
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.2x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-0.63%
Healthcare-0.67%
Biotech-0.34%
Biotech-0.34%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$161.242.7%
+US$7.4b
17.8%PE47.8x
INSM InsmedUS$55.05150.2%
+US$5.6b
181.7%PS28.1x
SMMT Summit TherapeuticsUS$8.69157.0%
+US$3.7b
379.8%PB137.9x
SGEN SeagenUS$228.744.5%
+US$1.8b
76.5%PS18.8x
GRPH Graphite BioUS$22.26539.7%
+US$1.1b
861.6%PB7.1x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

REGN

US$980.16

Regeneron Pharmaceuticals

7D

-0.5%

1Y

32.5%

GILD

US$64.27

Gilead Sciences

7D

-2.1%

1Y

-17.5%

SMMT

US$8.69

Summit Therapeutics

7D

157.0%

1Y

379.8%

ABBV

US$161.24

AbbVie

7D

2.7%

1Y

17.8%

INSM

US$55.05

Insmed

7D

150.2%

1Y

181.7%

BNTX

US$100.60

BioNTech

7D

3.8%

1Y

-7.0%

IMVT

US$25.39

Immunovant

7D

-12.3%

1Y

22.9%

EXAS

US$45.45

Exact Sciences

7D

-8.8%

1Y

-45.8%

SRPT

US$129.86

Sarepta Therapeutics

7D

5.2%

1Y

3.8%

BIIB

US$224.94

Biogen

7D

3.3%

1Y

-25.1%

VRTX

US$455.34

Vertex Pharmaceuticals

7D

-0.4%

1Y

36.4%

GRPH

US$22.26

Graphite Bio

7D

539.7%

1Y

861.6%

SGEN

US$228.74

Seagen

7D

4.5%

1Y

76.5%